# A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

> **NCT03151811** · PHASE3 · TERMINATED · sponsor: **Oncopeptides AB** · enrollment: 495 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melflufen
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03151811
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-12
- **Primary completion:** 2021-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 495 (ACTUAL)
- **Why stopped:** Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151811, "A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03151811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*